Novel combinations in participants with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma

Study identifier:D7986C00001

ClinicalTrials.gov identifier:NCT05702229

EudraCT identifier:2022-002840-29

CTIS identifier:N/A

Recruiting

Official Title

An Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Novel Combinations in Participants with Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Medical condition

gastric cancer

Phase

Phase 2

Healthy volunteers

No

Study drug

AZD2936, MEDI5752, FOLFOX, XELOX

Sex

All

Estimated Enrollment

80

Study type

Interventional

Age

18 Years - n/a

Date

Study Start Date: 16 Jan 2023
Estimated Primary Completion Date: 15 Aug 2025
Estimated Study Completion Date: 15 Feb 2026

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria